Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 4, 2004

View Archived Issues

Spotlight on glycogen synthase kinase-3

New platelet antiaggregatory agents discovered at Toray

A novel IKK-2 inhibitor and its use reported by GSK researchers

New cinnoline-based antitumor agents in early development at Nippon Kayaku

Tetrahydroquinoline-based antiinflammatory agents prepared and tested at Kyowa Hakko

Novel PI3K inhibitors and their use in rheumatoid arthritis and other disorders

New tubulin polymerization inhibitors covered by Cytopia patent

New antibacterial agents under evaluation at GeneSoft

CV Therapeutics and FDA agree to SPA for Ranexa

FTC clears Sanofi-Synthelabo's offer for Aventis

Prima BioMed initiates phase II study in ovarian cancer

Orally active agent against respiratory syncytial virus

Neuroprotective microtubule polymerizing agent set for clinical development

Synthetic indole compound effective against multidrug resistant tumors in vivo

Evotec OAI and ActivBiotics establish joint drug discovery project

Structural GenomiX acquires Troxatyl rights

Good efficacy and safety shown for long-term use of Sanctura

Orphan drug status for PYM-50018 for ALS

R-112 reduces symptoms of allergic rhinitis in phase II study

mondoBIOTECH and Bachem sign aviptadil agreement

Antituberculosis agent shows promising effects in pilot trial

OSI completes Tarceva NDA filing in NSCLC

Accelerated approval for Truvada

Lipitor approved to reduce risk of heart attacks

Epzicom receives FDA approval

Abbott submits NDA for Zemplar capsules

YM-348 reduces food intake, body weight gain in obesity model

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...